The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer

PURPOSE: Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway has been implicated in anti-estrogen resistance in breast cancer. We tested the therapeutic potential of the novel PI3K/mTOR dual inhibitor P7170 in a panel of anti-estrogen-sensitive and -resistant models of ER+ breast...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Bean, Jennifer R., Hosford, Sarah R., Symonds, Lynn K., Owens, Philip, Dillon, Lloye M., Yang, Wei, Shee, Kevin, Schwartz, Gary N., Marotti, Jonathan D., Muller, Kristen E., Rosenkranz, Kari M., Barth, Richard J., Chen, Vivian S., Agarwal, Veena R., Miller, Todd W.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4302040/
https://ncbi.nlm.nih.gov/pubmed/25491778
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3201-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars